Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.
This statement is based on a regulatory approval from the Health Service Executive:
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.